Gather the data
Papers, company data, market reports, patents and clinical trial records shaped early hypotheses.
A large global medical device company wanted to diagnose acute kidney injury and congestive heart failure noninvasively. We profiled established and emerging biomarkers and assessed which a wearable could measure in interstitial fluid.
The client is a large global medical device company. It wanted biomarkers that a wearable could measure in interstitial fluid.
Prescouter was asked to build a landscape of new and established noninvasive biomarkers for acute kidney injury and congestive heart failure, comparing their key traits and limitations.
What clinicians use today.
Biomarkers still in research.
Presence in interstitial fluid.
Papers, company data, market reports, patents and clinical trial records shaped early hypotheses.
An AI-driven review searched peer-reviewed research for reports on these biomarkers.
Interviews with subject matter experts checked what the secondary research suggested.
Prescouter assessed established and alternative biomarkers on presence in interstitial fluid, concentration range and strength of evidence. The resulting opportunity landscape will link acute kidney injury and heart failure biomarkers to current and future sensors for a wearable device.
Compared on traits and limits.
Concentration ranges and evidence.
A path to wearable monitoring.
The best biomarker is of little use if no device can read it. Linking biology to sensor capability early keeps development grounded.
Profile the biomarkers, test them with experts and link them to sensors. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]Pick a time on our calendar right now.
If you’d like to know the outcome of your submission, please leave your email address